Congenital methemoglobinemia is an unusual condition in which a large amount of intracellular hemoglobin exists as methemoglobin-pigment in which the hemoglobin iron is in the ferric state and incapable of carrying oxygen. The congenital type of methemoglobinemia is present from birth and is characterized by the constancy of the level of methemoglobin, by the relatively mild associated symptoms, and by polycythemia with no evidence of excessive blood destruction. There are 15 verified cases of congenital methemoglobinemia in the literature (1-10) and 10 additional cases of idiopathic methemoglobinemia (11) (12) (13) (14) (15) in which definite information as to the congenital aspect was lacking. In all of these cases the abnormalpigmentwas identified spectroscopically. Laboratory data: Hinton test for syphilis was negative; RBC was 6.5 million per mm.3; hematocrit was 58 per cent; Hb was 19 gms. per 100 cc.; WBC was 7,850 per mm.' with a normal differential count; reticulocytes were 2.2 per cent. Hypotonic saline fragility was normal. Bone marrow puncture showed only a normoblastic hyperplasia, consistent with his polycythemia. Urine and stool examinations were negative. Plasma proteins were 7.8 gms. per 100 cc. with 4.4 gms. of albumin; serum bilirubin was 0.5 mgm. per 100 cc. Venous pressure was 100 cm. of water; circulation time was 14 sec. (decholin) ; vital capacity was 4 liters. Bromsulfalein excretion test showed a retention of 5 per cent of the dye in the serum in 30 min. EKG was normal; BMR was -15 and -12 per cent. X-ray of the chest showed normal lung fields with a heart of normal size and shape. X-ray of the large bowel showed no abnormalities. Spectroscopic examination of the blood showed the absorption bands characteristic of methemoglobin. By difference between total pigment and oxygen capacity it was estimated that 45 per cent of the total blood pigment was in the form of methemoglobin. Subsequent determinations of methemoglobin were done by the colorimetric method of Evelyn and Malloy (16). This method was checked by the carbon monoxide capacity method of Van Slyke and Hiller (17) and found to be accurate to + 0.2 gm. in our hands.
Congenital methemoglobinemia is an unusual condition in which a large amount of intracellular hemoglobin exists as methemoglobin-pigment in which the hemoglobin iron is in the ferric state and incapable of carrying oxygen. The congenital type of methemoglobinemia is present from birth and is characterized by the constancy of the level of methemoglobin, by the relatively mild associated symptoms, and by polycythemia with no evidence of excessive blood destruction. There are 15 verified cases of congenital methemoglobinemia in the literature (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) and 10 additional cases of idiopathic methemoglobinemia (11) (12) (13) (14) (15) in which definite information as to the congenital aspect was lacking. In all of these cases the abnormalpigmentwas identified spectroscopically.
The subject of this study was a young man who presented the typical clinical picture of congenital methemoglobinemia. We 12 per cent. X-ray of the chest showed normal lung fields with a heart of normal size and shape. X-ray of the large bowel showed no abnormalities. Spectroscopic examination of the blood showed the absorption bands characteristic of methemoglobin. By difference between total pigment and oxygen capacity it was estimated that 45 per cent of the total blood pigment was in the form of methemoglobin. Subsequent determinations of methemoglobin were done by the colorimetric method of Evelyn and Malloy (16) . This method was checked by the carbon monoxide capacity method of Van Slyke and Hiller (17) and found to be accurate to + 0.2 gm. in our hands.
After a control period of one week in which the level of methemoglobin remained constant he was given 90 mgm. of methylene blue intravenously. In 10 minutes half of the methemoglobin disappeared and by 30 minutes over 95 per cent had disappeared. He was then able to exercise vigorously without headaches and breathlessness which had previously so limited his activity. During the course of the following five years he was treated with ascorbic acid and with methylene blue by mouth. It was found that 240 mgm. of methylene blue in enteric coated tablets per day were well tolerated and were sufficient to keep him free of cyanosis. Coincident with this treatment polycythemia and reticulocytosis subsided. No toxic effects from this long-sustained treatment have been observed.
The identity of the abnormal pigment in this case was established spectroscopically as methemoglobin. There was a well-defined absorption band at 630 u which disappeared after addition 265 of sodium cyanide or of sodium hydrosulfite (Na2S204) in vitro, or after injection of methylene blue in vivo.
Symptoms present in our patient and in others reported were those of anoxia due to the decreased oxygen-carrying capacity of the blood. In addition to this, Darling and Roughton (18) (2, 6, 10) .
Studies of the in vivo reduction rates of methemoglobin were performed by injecting, intravenously, 0.5 gm. of sodium nitrite into normal individuals and into the patient. Nitrite was chosen because it rapidly produced methemoglobin and was itself entirely gone from the blood stream by 60-90 minutes (21) . In both the normal subject and the patient the sodium nitrite caused formation of about 2.5 gms. of methemoglobin per 100 cc. of blood within 40 minutes. On the other hand, after three hours, half of the methemoglobin formed had disappeared in the normal subject while in the patient the methemoglobin level showed no tendency to fall even after seven hours ( Figure 5 ). This indicates that the normal mechanism for methemoglobin reduction fails to operate in this patient.
III. The methemoglobin reduction mechanism of the erythrocyte In vitro studies of methemoglobin reduction in the red cell have shown that this is an enzymatic process in which glucose and lactate act as hydrogen donors (22) (23) (24) . In view of this relationship, the carbohydrate metabolism of our patient's erythrocytes was investigated. The resting oxygen consumption measured in the Warburg manometric apparatus of 2 ml. of the patient's cells (27) were normal. Measurement of the other P partitions also showed nothing which indicated any abnormality of phosphorylation. These findings are summarized in Table I . To the extent of these studies we were unable to find any defect in the carbohydrate metabolism of the erythrocyte.
IV. Action of methylene blue Harrop and Barron in 1928 (31) demonstrated that the addition of methylene blue caused a tenfold increase in the oxygen consumption of mammalian red blood cells. Such an increase occurred to the same degree in our patient's erythrocytes as in the normal erythrocytes. This increase does not occur when the cells are washed free of glucose. When blood from the patient with congenital methemoglobinemia was treated with methylene blue in the presence of 100 mgm. per cent glucose there was complete reversion of the methemoglobin present to active hemoglobin. This 'The standard flavine adenine dinucleotide and the d-amino acid oxidase was generously furnished by Dr.
E. G. Ball. reversion was inhibited by M/300 iodoacetate. The beneficial therapeutic effect of methylene blue has been observed clinically for 15 years in secondary types of methemoglobinemia (32) (33) (34) and has been recently reported in congenital methemoglobinemia (8, 14) . The marked therapeutic effect of methylene blue in our patient suggests that it replaces some constituent of normal cells that is necessary for the enzymatic reduction of methemoglobin and that this is lacking in the cells of our patient.
V. Other oxidizing and reducing substances Since hydrogen peroxide is formed in certain enzymatic reactions and then is decomposed by intracellular catalase, it seemed possible that a deficiency of catalase could be responsible for the presence of methemoglobin. Accordingly the catalase content of the patient's erythrocytes was determined by a modification of the methods of Morgulis and Jusatz (35, 36) There are also substances present in blood cells and plasma that are capable of reducing methemoglobin. Ascorbic acid and glutathione are two such substances. This patient had blood levels of ascorbic acid averaging about 0.25 mgm. per cent compared to normal values of 1.5 to 2.0 mgm.
per cent (37) despite adequate dietary ascorbic acid. The reduced glutathione level of the patient's whole blood was 20 mgm. per cent as compared to normal values of 40 mgm. per cent (38) . One might consider that these substances represent a secondary line of defense of the body should the cell reconversion mechanism not func-tion. Certain circumstantial evidence indicates that this might be true. When hemoglobin or methemoglobin is injected intravenously in a dog an equilibrium point is reached at a methemoglobin concentration of 30 to 40 per cent of the total pigment (39, 40) . By coincidence the 11 cases of congenital methemoglobinemia in which the per cent methemoglobin was reported showed the same equilibrium concentration.
When 2 gms. of ascorbic acid were given intravenously the methemoglobin level dropped from 25 to 15 per cent in ten hours. On doses of 300 to 500 mgm. of ascorbic acid per day for two weeks it was possible to lower the level of methemoglobin to 8-10 per cent of the total pigment. The sluggishness of this reaction and the fact that d-ascorbic acid which is physiologically inert is equally as effective as the naturally occurring isomer suggest that the effect of ascorbic acid is due to its direct reducing action on methemoglobin (41, 42) rather than to restoration of the normal enzymatic reduction mechanism.
DISCUSSION
Studies on this case have emphasized the normal mechanism by which the organism is able to maintain the hemoglobin-methemoglobin equilibrium within the red cell at about 99.6 per cent in favor of the ferrous form which is essential for transport of oxygen (43) . There is undoubtedly steady formation of methemoglobin in the red cell, but the cells are capable of reducing the methemoglobin as soon as it is formed. In congenital methemoglobinemia we have shown that this mechanism fails to function, and it is pertinent to look further into the nature of this mechanism.
In 1930 Warburg (22) showed that methemoglobin formed in intact red cells could be reduced by the cells when glucose was added. This reduction of methemoglobin was accompanied by the disappearance of the glucose and the appearance of pyruvic acid. This effect could be inhibited by iodoacetate. Gibson (44) has recently shown that methemoglobin reduction can occur in the presence of fluoride, but there is accumulation of phosphoglycerate. These findings indicate that the reduction of methemoglobin is coupled with glycolysis. In the glycolytic process diphosphopyridine nucleotide (coenzyme I) is reduced and is available for reduction of methemoglobin. (Red cells also contain triphosphopyridine nucleotide [coenzyme II] which becomes reduced by the direct oxidation of glucose through phosphogluconic acid.) Gutmann (45) has shown that reduced pyridine. nucleotide will slowly reduce methemoglobin directly and this reaction can be accelerated by the addition of methylene blue.
In normal cells it is likely that a flavoprotein which is present acts, as in other tissues, as a carrier between the pyridine nucleotide and the iron porphyrin. Little is known about the nature and properties of the flavoprotein in the red cell. Studies of Gibson have shown that in abnormal cells of his patients with congenital methemoglobinemia there is no defect in that part of the cycle concerned with formation of reduced pyridine nucleotide. Since glycolysis was shown to take place normally in the cells of our patient it is probable that reduced pyridine nucleotide is also formed normally in his cells. Since methylene blue has such a pronounced effect on reducing the methemoglobin in his cells it seems likely that the defect lies in these substances which catalyze the reduction of methemoglobin by reduced pyridine nucleotide. Gibson concluded that this defect in his patients was a deficiency of the flavoprotein, the coenzyme factor. In heart muscle this factor has been shown to be a flavine adenine dinucleotide ' (46) . We analyzed for this substance using the d-amino acid oxidase as a test system and found it to be present in normal amounts in the cells of our patient. It is still a possibility that in his red cells this factor which is deficient is the flavine mononucleotide in which case the deficiency would not have been apparent by our method of analysis. It is also possible as both Kiese (47) and Gibson point out that the methylene blue does not function in a system already functioning actively (the coezyme I system) but rather enters into a secondary sluggish system (the coenzyme II system) and converts it into a rapidly active system. Further studies are necessary to find out what flavoproteins are present in the red cell and whether they have the capacity to reduce methemoglobin directly or require other as yet unknown factors. - 
